Institutional members access full text with Ovid®

Share this article on:

The Difference Between the Formal and the Functional Dose: The Case of the Patient on Thioridazine and Fluvoxamine


Journal of Psychiatric Practice®: May 2005 - Volume 11 - Issue 3 - p 192-196

SHELDON H. PRESKORN, MD, is Professor and Chairman, Department of Psychiatry, University of Kansas School of Medicine-Wichita, and Chief Executive Officer and Medical Director, Clinical Research Institute, Wichita, Kansas. He has more than 25 years of drug development research experience at all levels (i.e., preclinical through Phase IV) and has been a principal investigator on over 175 clinical trials including every antidepressant marketed in the United States over the last 20 years. Dr. Preskorn maintains a website at 〈〉 where readers can access previous columns and other publications.

© 2005 Lippincott Williams & Wilkins, Inc.